Robert Bazemore - Epizyme CEO and President and Director
EPZMDelisted Stock | USD 1.47 0.00 0.00% |
CEO
Mr. Robert B. Bazemore Jr. is President, Chief Executive Officer, Director of the Company. Mr. Bazemore served as the Chief Operating Officer of Synageva BioPharma Corporationration, a biopharmaceutical company developing therapeutic products for rare disorders. Prior to joining Synageva, Mr. Bazemore served in increasing levels of responsibility at Johnson Johnson, a healthcare company, including Vice President of Centocor Ortho Biotech Sales Marketing from 2008 to 2010, President of Janssen Biotech from January 2010 to October 2013 and Vice President of Global Surgery at Ethicon from October 2013 to September 2014. Prior to Johnson Johnson, Mr. Bazemore worked at Merck Co., Inc., or Merck, for eleven years, where he served in a variety of roles in medical affairs, sales and marketing since 2015.
Age | 50 |
Tenure | 9 years |
Phone | 617 229-5872 |
Web | www.epizyme.com |
Epizyme Management Efficiency
The company has return on total asset (ROA) of (38.96) % which means that it has lost $38.96 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (352.37) %, meaning that it created substantial loss on money invested by shareholders. Epizyme's management efficiency ratios could be used to measure how well Epizyme manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 254.44 M in liabilities. Epizyme has a current ratio of 5.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Epizyme until it has trouble settling it off, either with new capital or with free cash flow. So, Epizyme's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Epizyme sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Epizyme to invest in growth at high rates of return. When we think about Epizyme's use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 5 records | CEO Age | ||
Peter Christothoulou | Marchex | 42 | |
Richard Notebaert | Innovid Corp | 70 | |
David Reis | Stratasys | 63 | |
Nadav Goshen | Stratasys | N/A | |
Joe Allison | Stratasys | N/A |
Management Performance
Return On Equity | -352.37 | |||
Return On Asset | -38.96 |
Epizyme Leadership Team
Elected by the shareholders, the Epizyme's board of directors comprises two types of representatives: Epizyme inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Epizyme. The board's role is to monitor Epizyme's management team and ensure that shareholders' interests are well served. Epizyme's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Epizyme's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Shih, Vice President - Business Development | ||
Robert Bazemore, CEO and President and Director | ||
Richard Pops, Independent Director | ||
Kevin Conroy, Director | ||
Pamela Strode, Vice President - Regulatory Affairs and Quality Assurance | ||
Andrew Allen, Director | ||
Joseph Beaulieu, Principal Accounting Officer, Controller | ||
Robert Gould, CEO and President Secretary and Director | ||
Manisha Pai, IR Contact Officer | ||
Matthew Ros, COO | ||
Michael Boretti, Vice President - Business Development | ||
Stephen Garbacz, Principal Accounting Officer and Executive Director of Fin. | ||
Shefali Agarwal, Chief Medical Officer | ||
Susan Graf, Chief Business Officer | ||
Jason Fredette, Vice President of Investor Relations | ||
Robert Copeland, President of Research and Chief Scientific Officer | ||
Suzanne Fleming, Senior Vice President - Finance, Principal Accounting Officer, Treasurer | ||
Michael Giordano, Director | ||
Carl Goldfischer, Independent Director | ||
Paolo Tombesi, CFO | ||
Kenneth Bate, Independent Director | ||
Peter Ho, Chief Development Officer | ||
Beth Seidenberg, Independent Director | ||
David Mott, Independent Director | ||
Andrew Singer, CFO, Executive VP of Fin. and Admin. and Treasurer |
Epizyme Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Epizyme a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -352.37 | |||
Return On Asset | -38.96 | |||
Operating Margin | (582.15) % | |||
Current Valuation | 334.85 M | |||
Shares Outstanding | 103.89 M | |||
Shares Owned By Insiders | 0.58 % | |||
Shares Owned By Institutions | 90.32 % | |||
Number Of Shares Shorted | 5.49 M | |||
Price To Earning | (7.76) X | |||
Price To Book | 1.00 X |
Pair Trading with Epizyme
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Epizyme position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Epizyme will appreciate offsetting losses from the drop in the long position's value.Moving together with Epizyme Stock
0.83 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
0.81 | NONOF | Novo Nordisk AS | PairCorr |
Moving against Epizyme Stock
0.94 | URYL | United Royale Holdings | PairCorr |
0.88 | AZRH | Azure Holding Group | PairCorr |
0.73 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
0.73 | AAGH | America Great Health | PairCorr |
0.7 | WXIBF | WuXi Biologics | PairCorr |
The ability to find closely correlated positions to Epizyme could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Epizyme when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Epizyme - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Epizyme to buy it.
The correlation of Epizyme is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Epizyme moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Epizyme moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Epizyme can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Epizyme information on this page should be used as a complementary analysis to other Epizyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Epizyme Stock
If you are still planning to invest in Epizyme check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Epizyme's history and understand the potential risks before investing.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
CEOs Directory Screen CEOs from public companies around the world | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |